Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...

read more
What is the Metabolic Reset Diet – The Science

What is the Metabolic Reset Diet – The Science

The science, the promise, and the pitfalls The idea of a “metabolic reset” has gained traction across wellness media, social platforms, and weight management programmes. The premise is appealing: that metabolism can be “retrained” or “rebooted” through short-term...

read more
Functional Gut Clinic Launches GI Clinical Trials Division

Functional Gut Clinic Launches GI Clinical Trials Division

The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...

read more
GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK Makes $2.2 Billion Bid for RAPT Therapeutics

GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...

read more
What is the Metabolic Reset Diet – The Science

What is the Metabolic Reset Diet – The Science

The science, the promise, and the pitfalls The idea of a “metabolic reset” has gained traction across wellness media, social platforms, and weight management programmes. The premise is appealing: that metabolism can be “retrained” or “rebooted” through short-term...

read more
Functional Gut Clinic Launches GI Clinical Trials Division

Functional Gut Clinic Launches GI Clinical Trials Division

The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Ergonomic Design Considerations in Health Tech

Ergonomic Design Considerations in Health Tech

Why comfort and fit are essential design considerations in medical devices In many industries, product design rarely accounts for the variability of user profiles, with a focus on the ‘average’ person.  Headphones or even glasses too often do not account for head size...

read more
EQT Targets Oxford Biomedica in Major Biotech Takeover Bid

EQT Targets Oxford Biomedica in Major Biotech Takeover Bid

Oxford Biomedica has officially confirmed it is in preliminary discussions with the Swedish private equity giant EQT regarding a potential cash takeover. The announcement follows significant market speculation and a sharp rise in the company’s share price on January...

read more
UK Boosts Clinical Trials With Faster, Agile Regulation

UK Boosts Clinical Trials With Faster, Agile Regulation

Press Release: Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation  The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more...

read more
Five Ways AI Will Reshape Life Sciences in 2026

Five Ways AI Will Reshape Life Sciences in 2026

Why People, Process, and Purpose Matter Most Following a period of experimentation, life sciences is entering a pivotal new phase in AI adoption. The industry is shifting away from hype-driven pilots and toward proven, value-led applications that improve how therapies...

read more
Why Hormone Tracking will be a Key Health Trend for 2026

Why Hormone Tracking will be a Key Health Trend for 2026

Hormone health expert and bestselling author Dr Louise Newson explains why we'll all be tracking our hormones in 2026. The use of period tracking apps and menopause symptom tracker apps are at an all-time high. And it’s no wonder. These apps can be incredibly useful...

read more

Further News

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Editor’s note: This article reflects our plans and pricing as at July 2026. For current publishing options, see our Join and Publish page. Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare...

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

Daraxonrasib FDA Filing: What Happens Next for Pancreatic Cancer Patients?

The daraxonrasib FDA filing is nearing completion, marking a pivotal regulatory moment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Revolution Medicines announced on 7 July 2026 that its rolling submission of a New Drug Application (NDA) to...

Digital Twin: The Future of Pharmaceutical Manufacturing Science

Pharmaceutical manufacturing is entering a new scientific era. For decades, the industry has relied on validated processes, fixed control strategies, laboratory testing and carefully documented batch records to prove that medicines are made consistently and safely....

How AI-Enabled Functional Precision Oncology Is Personalizing Treatment

When the Standard Playbook Runs Out  In pediatric and adult oncology alike, there is a recognizable moment when the standard treatment playbook is exhausted. For patients with rare, relapsed, or treatment-resistant cancers, guidelines built for the common case offer...

The Infrastructure Gap Behind the GLP-1 Boom

The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...

How Climate Change is Redrawing Europe’s Disease Landscape

The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health.  New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...

A Path to Rebuilding American Manufacturing for Lab Consumables

Amid today's geopolitical tensions, supply chain vulnerability is emerging as an increasingly central concern, and, in the case of life science consumables, one that places the health of the public at risk. The issue itself, however, is far from new. In December 2020...

Weekly News Roundup | 13 July 2026

Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.